Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Early prediction of liver disease using conventional risk factors and gut microbiome-augmented gradient boosting

Yang Liu, Guillaume Meric, Aki S. Havulinna, Shu Mei Teo, Matti Ruuskanen, Jon Sanders, Qiyun Zhu, Anupriya Tripathi, Karin Verspoor, Susan Cheng, Mo Jain, Pekka Jousilahti, Yoshiki Vazquez-Baeza, Rohit Loomba, Leo Lahti, Teemu Niiranen, Veikko Salomaa, Rob Knight, Michael Inouye
doi: https://doi.org/10.1101/2020.06.24.20138933
Yang Liu
1Cambridge Baker Systems Genomics Initiative, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia
2Department of Clinical Pathology, Melbourne Medical School, The University of Melbourne, Melbourne, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guillaume Meric
1Cambridge Baker Systems Genomics Initiative, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia
3Department of Infectious Diseases, Central Clinical School, Monash University, Melbourne, Victoria 3004, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aki S. Havulinna
4Department of Public Health Solutions, Finnish Institute for Health and Welfare, Helsinki, Finland
5Institute of Molecular Medicine Finland, University of Helsinki, Helsinki, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shu Mei Teo
1Cambridge Baker Systems Genomics Initiative, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia
6Cambridge Baker Systems Genomics Initiative, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matti Ruuskanen
7Department of Medicine, Turku University Hospital and University of Turku, Turku, Finland
8Department of Future Technologies, University of Turku, Turku, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jon Sanders
9Department of Pediatrics, School of Medicine, University of California San Diego, La Jolla, California, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Qiyun Zhu
9Department of Pediatrics, School of Medicine, University of California San Diego, La Jolla, California, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anupriya Tripathi
9Department of Pediatrics, School of Medicine, University of California San Diego, La Jolla, California, USA
10Division of Biological Sciences, University of California San Diego, La Jolla, California, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karin Verspoor
11School of Computing and Information Systems, University of Melbourne, Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susan Cheng
12Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mo Jain
9Department of Pediatrics, School of Medicine, University of California San Diego, La Jolla, California, USA
13Center for Microbiome Innovation, University of California San Diego, La Jolla, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pekka Jousilahti
4Department of Public Health Solutions, Finnish Institute for Health and Welfare, Helsinki, Finland
7Department of Medicine, Turku University Hospital and University of Turku, Turku, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yoshiki Vazquez-Baeza
13Center for Microbiome Innovation, University of California San Diego, La Jolla, CA, USA
14Department of Computer Science & Engineering, Jacobs School of Engineering, University of California San Diego, La Jolla, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rohit Loomba
15NAFLD Research Center, Department of Medicine, University of California San Diego, La Jolla, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leo Lahti
7Department of Medicine, Turku University Hospital and University of Turku, Turku, Finland
8Department of Future Technologies, University of Turku, Turku, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Teemu Niiranen
7Department of Medicine, Turku University Hospital and University of Turku, Turku, Finland
8Department of Future Technologies, University of Turku, Turku, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Veikko Salomaa
4Department of Public Health Solutions, Finnish Institute for Health and Welfare, Helsinki, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rob Knight
9Department of Pediatrics, School of Medicine, University of California San Diego, La Jolla, California, USA
13Center for Microbiome Innovation, University of California San Diego, La Jolla, CA, USA
14Department of Computer Science & Engineering, Jacobs School of Engineering, University of California San Diego, La Jolla, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Inouye
1Cambridge Baker Systems Genomics Initiative, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia
2Department of Clinical Pathology, Melbourne Medical School, The University of Melbourne, Melbourne, Victoria, Australia
6Cambridge Baker Systems Genomics Initiative, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
16Health Data Research UK Cambridge, Wellcome Genome Campus and University of Cambridge, Cambridge, UK
17British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
18British Heart Foundation Centre of Research Excellence, University of Cambridge, Cambridge, UK
19National Institute for Health Research Cambridge Biomedical Research Centre, University of Cambridge and Cambridge University Hospitals, Cambridge, UK
20The Alan Turing Institute, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: minouye@baker.edu.au mi336@medschl.cam.ac.uk
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Gut microbiome sequencing has shown promise as a predictive biomarker for a wide range of diseases, including classification of liver disease and severity grading. However, the potential of gut microbiota for prospective risk prediction of liver disease has not been assessed. Here, we utilise shallow gut metagenomic sequencing data of a large population-based cohort (N=>7,115) and ∼15 years of electronic health register follow-up together with machine-learning to investigate the predictive capacity of gut microbial predictors, individually and in conjunction with conventional risk factors, for incident liver disease and alcoholic liver disease. Separately, conventional and microbiome risk factors showed comparable predictive capacity for incident liver disease. However, microbiome augmentation of conventional risk factor models using gradient boosted classifiers significantly improved performance, with average AUROCs of 0.834 for incident liver disease and 0.956 for alcoholic liver disease (AUPRCs of 0.185 and 0.304, respectively). Disease-free survival analysis showed significantly improved stratification using microbiome-augmented risk models as compared to conventional risk factors alone. Investigation of predictive microbial signatures revealed a wide range of bacterial taxa, including those previously associated with hepatic function and disease. This study supports the potential clinical validity of gut metagenomic sequencing to complement conventional risk factors for risk prediction of liver diseases.

Competing Interest Statement

VS has received honoraria for consulting from Novo Nordisk and Sanofi and travel support from Novo Nordisk. He also has ongoing research collaboration with Bayer Ltd (All unrelated to the present study). RL serves as a consultant or advisory board member for Anylam/Regeneron, Arrowhead Pharmaceuticals, AstraZeneca, Bird Rock Bio, Boehringer Ingelheim, Bristol-Myer Squibb, Celgene, Cirius, CohBar, Conatus, Eli Lilly, Galmed, Gemphire, Gilead, Glympse bio, GNI, GRI Bio, Inipharm, Intercept, Ionis, Janssen Inc., Merck, Metacrine, Inc., NGM Biopharmaceuticals, Novartis, Novo Nordisk, Pfizer, Prometheus, Promethera, Sanofi, Siemens, and Viking Therapeutics. In addition, his institution has received grant support from Allergan, Boehringer-Ingelheim, Bristol-Myers Squibb, Cirius, Eli Lilly and Company, Galectin Therapeutics, Galmed Pharmaceuticals, GE, Genfit, Gilead, Intercept, Grail, Janssen, Madrigal Pharmaceuticals, Merck, NGM Biopharmaceuticals, NuSirt, Pfizer, pH Pharma, Prometheus, and Siemens. He is also co-founder of Liponexus, Inc.

Funding Statement

VS was supported by the Finnish Foundation for Cardiovascular Research. MI was supported by the Munz Chair of Cardiovascular Prediction and Prevention. ASH was supported by the Academy of Finland, grant no. 321356. LL was supported by Academy of Finland (295741, 307127). TN was supported by the Emil Aaltonen Foundation, the Paavo Nurmi Foundation, the Finnish Medical Foundation, and the Academy of Finland (grant no. 321351). RL receives funding support from NIEHS (5P42ES010337), NCATS (5UL1TR001442), NIDDK (U01DK061734, R01DK106419, P30DK120515, R01DK121378, R01DK124318), and DOD PRCRP (W81XWH-18-2-0026). This study was supported by the Victorian Government Operational Infrastructure Support (OIS) program, and by core funding from: the UK Medical Research Council (MR/L003120/1), the British Heart Foundation (RG/13/13/30194; RG/18/13/33946) and the National Institute for Health Research [Cambridge Biomedical Research Centre at the Cambridge University Hospitals NHS Foundation Trust] [*]. This work was supported by Health Data Research UK, which is funded by the UK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation and Wellcome. *The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study protocol of FINRISK 2002 was approved by the Coordinating Ethical Committee of the Helsinki and Uusimaa Hospital District (Ref. 558/E3/2001). All participants signed an informed consent. The study was conducted according to the World Medical Association Declaration of Helsinki on ethical principles.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The data for the present study are available with a written application to the THL Biobank as instructed in the website of the Biobank: https://thl.fi/en/web/thl-biobank/for-researchers. Predictive models are available at https://doi.org/10.26188/12554573.v1

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted June 25, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Early prediction of liver disease using conventional risk factors and gut microbiome-augmented gradient boosting
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Early prediction of liver disease using conventional risk factors and gut microbiome-augmented gradient boosting
Yang Liu, Guillaume Meric, Aki S. Havulinna, Shu Mei Teo, Matti Ruuskanen, Jon Sanders, Qiyun Zhu, Anupriya Tripathi, Karin Verspoor, Susan Cheng, Mo Jain, Pekka Jousilahti, Yoshiki Vazquez-Baeza, Rohit Loomba, Leo Lahti, Teemu Niiranen, Veikko Salomaa, Rob Knight, Michael Inouye
medRxiv 2020.06.24.20138933; doi: https://doi.org/10.1101/2020.06.24.20138933
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Early prediction of liver disease using conventional risk factors and gut microbiome-augmented gradient boosting
Yang Liu, Guillaume Meric, Aki S. Havulinna, Shu Mei Teo, Matti Ruuskanen, Jon Sanders, Qiyun Zhu, Anupriya Tripathi, Karin Verspoor, Susan Cheng, Mo Jain, Pekka Jousilahti, Yoshiki Vazquez-Baeza, Rohit Loomba, Leo Lahti, Teemu Niiranen, Veikko Salomaa, Rob Knight, Michael Inouye
medRxiv 2020.06.24.20138933; doi: https://doi.org/10.1101/2020.06.24.20138933

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Genetic and Genomic Medicine
Subject Areas
All Articles
  • Addiction Medicine (62)
  • Allergy and Immunology (141)
  • Anesthesia (44)
  • Cardiovascular Medicine (408)
  • Dentistry and Oral Medicine (67)
  • Dermatology (47)
  • Emergency Medicine (141)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (171)
  • Epidemiology (4809)
  • Forensic Medicine (3)
  • Gastroenterology (177)
  • Genetic and Genomic Medicine (671)
  • Geriatric Medicine (70)
  • Health Economics (187)
  • Health Informatics (621)
  • Health Policy (314)
  • Health Systems and Quality Improvement (200)
  • Hematology (85)
  • HIV/AIDS (155)
  • Infectious Diseases (except HIV/AIDS) (5280)
  • Intensive Care and Critical Care Medicine (326)
  • Medical Education (91)
  • Medical Ethics (24)
  • Nephrology (73)
  • Neurology (677)
  • Nursing (41)
  • Nutrition (110)
  • Obstetrics and Gynecology (124)
  • Occupational and Environmental Health (203)
  • Oncology (438)
  • Ophthalmology (138)
  • Orthopedics (36)
  • Otolaryngology (88)
  • Pain Medicine (35)
  • Palliative Medicine (15)
  • Pathology (127)
  • Pediatrics (193)
  • Pharmacology and Therapeutics (129)
  • Primary Care Research (84)
  • Psychiatry and Clinical Psychology (767)
  • Public and Global Health (1796)
  • Radiology and Imaging (321)
  • Rehabilitation Medicine and Physical Therapy (138)
  • Respiratory Medicine (255)
  • Rheumatology (86)
  • Sexual and Reproductive Health (68)
  • Sports Medicine (61)
  • Surgery (100)
  • Toxicology (23)
  • Transplantation (28)
  • Urology (37)